Chapter 13: Weight Loss Peptides Beyond GLP-1: Amylin, Melanocortins, Setmelanotide, and the Appetite Regulation System

"We found the gene, we found the hormone, we gave it to the mice, and the mice got thin. It was the most exciting result any of us had ever seen. Then we gave it to people." — a fair paraphrase of how the leptin decade felt from inside it

Overview

In 1994 a gene was cloned that appeared to explain obesity.

Mice carrying two defective copies of it ate enormously and became severely obese. Give those mice the protein the gene encodes and they stopped overeating and lost weight — dramatically, reproducibly, in a way that looked less like a treatment than like a correction. The protein was named leptin, from the Greek for thin.

The implication seemed obvious. Obesity was a hormone deficiency. Find the deficiency, supply the hormone, done — the same shape as insulin for type 1 diabetes, the cleanest kind of medicine there is.

It did not work, and understanding why is the most useful thing in this chapter.

Because leptin was not deficient in most people with obesity. It was elevated — often substantially. The system was not failing to produce the signal; it was failing to respond to it. And a decade of enormous scientific effort produced a drug that is genuinely miraculous for a few dozen people in the world with a rare genetic condition, and does essentially nothing for everyone else.

That pattern — spectacular in a tiny genetically defined population, absent in the general one — recurs throughout this chapter. It is the shape of setmelanotide's story too, and it is the single most important thing to understand about why appetite pharmacology is hard.

This chapter covers the rest of the appetite system: amylin, the melanocortins, PYY, ghrelin, and the supplements that claim to work on all of it. Chapter 8's case study covered the weight-loss drugs that failed on safety. This one covers the ones that failed on efficacy, and the reasons are different and more interesting.

In this chapter, you will learn to:

• Explain why appetite is a network with redundancy rather than a switch
• Tell the leptin story accurately, including what it did achieve
• Describe amylin's mechanism and how a two-molecule combination differs from a dual agonist
• Explain the melanocortin pathway and setmelanotide's extraordinary narrowness
• Say why ghrelin and PYY keep failing
• State why single-target appetite drugs underperform
• Dismantle a "natural GLP-1 booster" claim using physiology rather than skepticism

Learning Paths

💊 GLP-1 — §13.7 explains why the drugs you came here for succeeded where a dozen others failed. It is the best available answer to "what made these different?" 🏋️ Performance — §13.8 is a transferable Hype Check; the reasoning applies to any supplement claiming to raise an endogenous signal. 🔬 Science — full read; §13.1 and §13.7 are the systems argument and §13.2 is the field's most instructive failure. 💄 Cosmetic — skip, apart from §13.8's reasoning pattern. 🏥 Clinical — §13.2 and §13.5 are what to say to a patient who has read that obesity is "a hormone problem." The honest answer is more interesting than yes or no.

13.1 Appetite is a network, not a switch

Start with the architecture, because every failure in this chapter follows from it.

Your body regulates energy balance the way it regulates temperature and blood pressure: with a defended set point, multiple redundant inputs, and counter-regulation that opposes displacement in either direction.

THE APPETITE NETWORK — a schematic, and deliberately incomplete

  SIGNALS FROM THE PERIPHERY                    INTEGRATION                OUTPUT
  ─────────────────────────────                 ───────────                ──────
  FAT TISSUE
    leptin ──────── "how much stored energy" ──┐
                                                │
  GUT (meal-triggered)                          │      ┌──────────────┐
    GLP-1 ───────── "food is arriving" ────────┼─────▶│ HYPOTHALAMUS │
    GIP ──────────                              │      │  (arcuate    │──▶ HUNGER
    PYY ─────────── "meal is finishing" ───────┤      │   nucleus)   │    SATIETY
    CCK ──────────                              │      │              │    ENERGY
    ghrelin ─────── "stomach is empty" ────────┤      │  POMC → αMSH │    EXPENDITURE
                                                │      │  AgRP/NPY    │
  PANCREAS                                      │      └──────┬───────┘
    insulin ─────── "glucose is available" ────┤             │
    amylin ──────── "co-secreted with insulin" ┘             ▼
                                                        BRAINSTEM
  NEURAL                                                (NTS, area postrema)
    vagal afferents ─ stretch, nutrient sensing ─────────────┘

  AT LEAST A DOZEN SIGNALS. Remove one and the others largely compensate.
  THIS IS THE WHOLE PROBLEM.

Three features of this architecture matter, and each kills a class of drug.

Redundancy. No single signal is necessary. Block ghrelin and other orexigenic pathways continue. Supply PYY and other satiety signals were already operating. A system with a dozen partly overlapping inputs is robust against the loss of any one — which is excellent engineering for survival and terrible news for a drug that targets one node.

Counter-regulation. Push energy intake down and the system responds: appetite signaling increases, energy expenditure falls modestly, and the defended set point is not lowered. Chapter 3 §3.6 covered this architecture in glucose regulation. It operates here too, and it is why weight regain after any intervention — dietary, surgical, or pharmacological — is the norm rather than the exception.

Asymmetry. The system defends much harder against weight loss than against weight gain. From an evolutionary standpoint this is unsurprising and it is deeply inconvenient. It means an appetite drug is not fighting a neutral system; it is fighting one that is actively better at resisting the direction you want.

🔍 Check Your Understanding

1. Why does redundancy in the appetite network make single-target drugs likely to underperform?
2. What does "defended set point" mean, and what does it predict about discontinuation?
3. Why would you expect the system to resist weight loss more strongly than weight gain?

13.2 Leptin: the discovery that promised everything

The leptin story is worth telling properly, because it is usually told as a failure and it is not one.

What was found. The ob/ob mouse — obese, hyperphagic, with a recessive mutation — had been studied for decades. In 1994 the gene was cloned and the protein identified. Mice lacking it are massively obese; supplying it normalizes their eating and their weight.

Leptin is produced by fat tissue in proportion to fat mass. This is the elegant part: it is a signal reporting how much stored energy you have. More fat, more leptin, and — in the model — less hunger. A negative feedback loop for body weight, exactly as Chapter 3 would predict.

Why everyone expected a drug. The logic was insulin's: identify the hormone, find the deficiency, replace it. The parallel felt exact.

What actually happened. People with common obesity do not have low leptin. They have high leptin — appropriately so, since leptin tracks fat mass. The signal was being sent loudly and not acted on. This is leptin resistance, and it meant supplying more leptin was supplying more of a message that was already being ignored.

Trials of leptin in common obesity produced modest and inconsistent effects. The drug did not work, not because the biology was wrong but because the disease was not what the model implied.

THE LEPTIN REVERSAL

  WHAT THE MODEL PREDICTED            WHAT WAS FOUND
  ────────────────────────            ──────────────
  obesity = leptin deficiency         obesity = HIGH leptin
        ▼                                   ▼
  supply leptin                       the signal is already maximal
        ▼                                   ▼
  hunger falls, weight falls          adding more changes little
        ▼                                   ▼
  a cure                              leptin RESISTANCE — a
                                      different problem entirely

  THE MODEL WAS NOT WRONG ABOUT THE HORMONE.
  IT WAS WRONG ABOUT WHICH DISEASE IT EXPLAINED.

What leptin did achieve

It works spectacularly in congenital leptin deficiency.

A very small number of people worldwide have loss-of-function mutations in the leptin gene. They present in childhood with extreme hyperphagia and severe obesity. Leptin replacement in these individuals is transformative — appetite normalizes, weight falls substantially, and associated endocrine abnormalities correct.

This is a genuine, dramatic, life-changing treatment. It benefits a population measured in dozens.

And it established the field. Leptin's discovery demonstrated that adipose tissue is an endocrine organ, opened the entire study of energy-balance signaling, and identified the hypothalamic circuitry that §13.4 covers. The GLP-1 drugs exist partly because leptin taught the field where to look.

📊 Evidence Rating — leptin for congenital leptin deficiency

Claim: Recombinant leptin (metreleptin) normalizes appetite and reduces weight in individuals with congenital leptin deficiency.

Rating: ✅ Strong clinical evidence.

Why: A dramatic, reproducible response in a genetically defined population where the deficiency is total — the purest replacement case in this chapter. Approved for use in specified lipodystrophy indications; leptin deficiency itself is vanishingly rare.

What would change it: essentially nothing for this claim.

📊 Evidence Rating — leptin for common obesity

Claim: Leptin administration produces meaningful weight loss in adults with common obesity.

Rating: ❌ Hype outpaces evidence — and here the evidence is not absent but negative.

Why: Circulating leptin is already elevated in common obesity; the problem is resistance rather than deficiency. Trials produced modest and inconsistent effects.

What would change it: an intervention that restored leptin sensitivity rather than supplying more ligand would be a different claim entirely, and is an active research direction.

Two ratings, one molecule, and they could not be further apart. This is Chapter 5's rule 6 in its cleanest form, and it is worth pausing on: a source describing "leptin" as effective or ineffective without naming the population has destroyed the only information that matters.

13.3 Amylin: pramlintide and cagrilintide

Amylin (islet amyloid polypeptide) is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells. It slows gastric emptying, suppresses inappropriate glucagon secretion after meals, and promotes satiety.

Notice that this overlaps substantially with GLP-1's actions (Chapter 7's actions ② and ③) while arriving from a different tissue by a different route. That overlap is the redundancy of §13.1, observed in a specific pair of hormones.

Because amylin is co-secreted with insulin, people with type 1 diabetes are deficient in it too — a fact that is easy to miss and that makes amylin replacement conceptually a replacement rather than an override in that population.

Pramlintide is a synthetic amylin analog, engineered because native human amylin aggregates and is unsuitable as a drug. It is approved as an adjunct to mealtime insulin in type 1 and type 2 diabetes, where it improves post-meal glucose control and produces modest weight effects.

Cagrilintide is a long-acting amylin analog developed specifically for weight management, and CagriSema combines it with semaglutide.

🧬 The Molecule — why CagriSema is not tirzepatide

This distinction is worth getting right because the two products are frequently described the same way.

Tirzepatide is ONE molecule that activates TWO receptors. One pharmacokinetic profile; a ratio of activity at the two targets that is fixed by the molecule's structure and cannot be adjusted without designing a different molecule.

CagriSema is TWO molecules in ONE injection. Two pharmacokinetic profiles; a ratio that can be tuned by changing the amount of each component.

The trade-off runs both ways. Tunability is a genuine advantage — a fixed ratio is a bet you cannot revise. But two molecules mean two absorption profiles, two clearance rates, and two sets of immunogenicity and stability questions, and the ratio the patient actually experiences drifts over the dosing interval in a way a single molecule's does not.

Neither architecture is obviously better, and which wins is an empirical question that the respective development programs are in the process of answering.

📊 Evidence Rating — pramlintide as adjunct therapy in insulin-treated diabetes

Claim: Pramlintide, added to mealtime insulin, improves postprandial glucose control and produces modest weight reduction in insulin-treated diabetes.

Rating: ✅ for this narrow claim in this population.

Why: Approved for this indication on the basis of randomized trials; the effect on post-meal glucose is consistent and the weight effect is real and modest.

What would change it: little for the claim as stated. Note what it does not cover: it is not a weight-loss drug for people without diabetes, and its clinical use has been limited by administration burden and hypoglycemia risk in combination with insulin.

📊 Evidence Rating — cagrilintide and CagriSema for weight management

Claim: Long-acting amylin analogs, alone or combined with semaglutide, produce clinically meaningful weight loss.

Rating: ⚠️ Promising but preliminary, as of 2026.

Why: Real randomized human data supporting substantial effects, with a late-stage program ongoing. Reported results have in some analyses been less dramatic than earlier figures suggested — the Phase 2 optimism pattern of Chapter 9.

What would change it: completed Phase 3 reporting both estimands, plus cardiovascular outcome data. Check current sources for figures; this book's information is current only to 2026 and this program is moving.

13.4 The melanocortin pathway

Deep in the hypothalamus sits the circuit that most directly sets appetite, and it is worth understanding because it is where the genetic cases live.

THE LEPTIN–MELANOCORTIN PATHWAY — the core appetite circuit

              LEPTIN (from fat) ──┐
              INSULIN ────────────┤
                                  ▼
        ┌─────────────────────────────────────────────┐
        │        ARCUATE NUCLEUS (hypothalamus)       │
        │                                             │
        │   POMC neurons          AgRP/NPY neurons    │
        │   (stimulated by        (INHIBITED by       │
        │    leptin)               leptin)            │
        │        │                     │              │
        │        ▼                     ▼              │
        │   POMC is cleaved       releases AgRP,      │
        │   to α-MSH              which BLOCKS        │
        │        │                the receptor        │
        └────────┼─────────────────────┼──────────────┘
                 │                     │
                 ▼                     ▼
        ┌──────────────────────────────────────┐
        │   MC4R  (melanocortin-4 receptor)    │
        │   α-MSH activates it → LESS HUNGER   │
        │   AgRP blocks it     → MORE HUNGER   │
        └──────────────────────────────────────┘

  An accelerator and a brake converging on ONE receptor. Break any component
  — POMC, the leptin receptor, MC4R itself — and severe early-onset obesity
  follows. These are the MONOGENIC obesities.

Two things about this circuit.

It is where the rare severe obesities come from. Loss-of-function mutations in POMC, in the leptin receptor (LEPR), in MC4R, and in related genes produce early-onset, severe, hyperphagic obesity. MC4R variants are the most common known monogenic contributor to obesity, and even heterozygous variants are associated with increased weight.

And it is downstream of leptin, which is why it matters for §13.2. A person with leptin receptor deficiency has plenty of leptin and no way to hear it. Supplying more leptin does nothing. But supplying something that acts downstream of the broken step could work — and that is exactly the setmelanotide idea.

13.5 Setmelanotide: spectacular, and for almost nobody

Setmelanotide is an 8-amino-acid cyclic MC4R agonist. It activates the receptor directly, bypassing everything upstream of it.

It is approved for chronic weight management in obesity due to specified rare genetic deficiencies in the leptin–melanocortin pathway — including POMC deficiency and leptin receptor deficiency, and subsequently extended to certain related conditions.

In those patients the effect is dramatic. Substantial weight loss, and — reported as more significant by patients and families — a marked reduction in the relentless hunger that characterizes these conditions.

And it is not a general obesity drug. In common obesity the pathway is intact; there is no broken upstream step to bypass. The population it treats is measured in the low thousands worldwide at most.

💊 In the Clinic — what setmelanotide actually teaches

Three lessons, and the third is the one that transfers.

Mechanism is confirmed. Setmelanotide's efficacy proves the melanocortin pathway is genuinely causal in appetite regulation, not merely correlated with it. That is real knowledge and it was not free.

Genetic definition is what makes it work. The drug works because the patients were selected by a molecular diagnosis, not by a phenotype. Everyone in the trial had a specific broken step that the drug bypasses. This is precision medicine functioning exactly as advertised — and it is rare.

And a confirmed mechanism does not license a broad claim. MC4R agonism works when MC4R signaling is deficient. It does not follow that MC4R agonism helps when the pathway is working. This is Chapter 2's warning in its most concrete form: the mechanism is not merely plausible here, it is proven — and it still does not extend beyond the population where the specific defect exists.

When you meet a compound whose supporters point to a proven mechanism, this is the case to think about.

📊 Evidence Rating — setmelanotide for obesity due to specified rare genetic deficiencies

Claim: Setmelanotide reduces weight and hyperphagia in individuals with obesity due to specified genetic deficiencies in the leptin–melanocortin pathway.

Rating: ✅ Strong clinical evidence for this population.

Why: Approved on the basis of trials in genetically defined patients, with substantial and consistent effects on both weight and hunger.

What would change it: little for this claim.

What it explicitly does NOT cover: common polygenic obesity, in which the pathway is intact. The rating does not extend there and no evidence supports extending it.

13.6 PYY, ghrelin, and the targets that keep failing

Two more signals, both extensively pursued, neither producing a drug.

Peptide YY (PYY) is released from intestinal L cells — the same cells that make GLP-1 (Chapter 7 §7.2) — after meals, and it reduces food intake. Infusion studies in humans reduce subsequent eating. It looked like an obvious target.

Why it has failed so far: delivery is difficult, the effect in infusion studies is modest and short-lived, and nausea has been dose-limiting in several programs. The redundancy problem applies — supplying more of one satiety signal into a system with several does not straightforwardly produce proportional benefit.

Ghrelin rises before meals and falls afterward, and it stimulates appetite. It is the only substantially orexigenic gut hormone known, which made blocking it seem obvious.

Why blocking it has failed: ghrelin's role appears less dominant than the "hunger hormone" nickname suggests, and blocking one appetite-stimulating pathway leaves the others. Ghrelin also has metabolic and cardiovascular roles beyond appetite, so blockade is not clean. Notably, ghrelin receptor agonists — the opposite intervention — have been pursued for appetite stimulation in cachexia and for growth hormone release (Chapter 15), which is a better fit to what the system actually does.

⚠️ Hype Check — "the hunger hormone"

Ghrelin's nickname is the same error as oxytocin's "love hormone," and it does the same damage.

What's true: ghrelin rises before meals, falls after, and administering it increases food intake in humans. The association with hunger is real.

What the nickname implies and the evidence does not support: that ghrelin is the hunger signal, that suppressing it would suppress hunger, and that its level explains why people eat. Blocking it has not produced a useful drug, ghrelin has substantial roles unrelated to appetite, and appetite persists perfectly well without it.

The general lesson: a hormone named for one of its effects will be reasoned about as though that effect were its purpose. Chapter 21 will make this point about oxytocin at length. The nickname is a compression, and compressions are where the errors live.

13.7 Why single-target appetite drugs underperform

Assemble the chapter. Five compounds, five failures or near-failures, and one common structure.

WHY THEY FAIL — the pattern

  LEPTIN            targeted a signal that was ALREADY MAXIMAL
                    → resistance, not deficiency

  PYY               added one satiety signal to a system with several
                    → redundancy absorbed it

  GHRELIN BLOCKADE  removed one hunger signal from a system with several
                    → redundancy absorbed it

  MC4R AGONISM      works ONLY where the upstream pathway is broken
                    → precision, not generality

  SINGLE-ACTION     any intervention on one node meets counter-regulation
  APPETITE DRUGS    defending a set point that was never reset

  ─────────────────────────────────────────────────────────────────────
  AND WHY GLP-1 AGONISTS DIFFERED:
  · FOUR simultaneous actions, not one (Ch 7 §7.3)
  · they act on a system whose specific job is responding to meals,
    rather than on a broad neuromodulatory system (Ch 8 CS2)
  · sustained supraphysiological exposure through partly different
    routes than the endogenous signal uses (Ch 7 §7.6)
  · and the effect is LARGE enough to outweigh counter-regulation
    while the drug is present — but NOT to remove the set point,
    which is why weight returns on stopping (Ch 8 §8.9)
  ─────────────────────────────────────────────────────────────────────

The argument, stated plainly: a redundant network defending a set point is robust against single-node interventions, and the successful drugs succeeded partly by hitting several nodes at once and partly by pushing much harder than physiology ever does.

Two honest caveats, because this explanation is tidier than the evidence.

It is partly retrospective. The account fits what happened. It did not predict it — GLP-1 was not selected for having four actions, and the appetite effect was a secondary observation in diabetes trials. Explanations that fit after the fact are cheap, and this book should say so about its own.

And it does not explain the magnitude. Multi-node action explains why GLP-1 agonists beat leptin. It does not explain why sustained receptor agonism produces fifteen to twenty percent weight loss when endogenous incretin signaling produces nothing of the kind. Chapter 7 §7.6 offered a candidate — the drug may be a different signal rather than more of the same one — and it remains a candidate.

13.8 "Natural GLP-1 boosters" and the supplement claim

A large and growing product category claims to raise your own GLP-1 — through fiber, specific foods, bitter compounds, probiotics, or proprietary blends.

Take the claim seriously first, because part of it is true.

What is genuinely established: nutrient arrival in the intestine triggers GLP-1 release from L cells (Chapter 7 §7.2). Different macronutrients and food forms produce different responses. Fermentable fiber reaching the distal intestine, where L cells are concentrated, can increase GLP-1 secretion. Some foods do modestly and measurably raise postprandial GLP-1. This is real physiology and the supplement industry did not invent it.

Now apply Chapter 7's numbers, and the claim collapses on four separate grounds.

WHY "BOOSTING" ENDOGENOUS GLP-1 CANNOT REPRODUCE THE DRUG

  ① HALF-LIFE
     Endogenous GLP-1 is destroyed by DPP-4 in ~1–2 MINUTES. Whatever you
     raise is gone before the next thought. Semaglutide's half-life is ~1 WEEK.

  ② MAGNITUDE
     A dietary intervention produces a modest increase in a postprandial peak.
     A therapeutic agonist produces SUSTAINED SUPRAPHYSIOLOGICAL receptor
     occupancy. These differ by orders of magnitude, not by degree.

  ③ THE ROUTE MAY DIFFER
     Endogenous GLP-1 acts largely LOCALLY, via vagal afferents, because so
     little survives to circulate. The drugs act systemically, including at
     brain regions with a leaky blood-brain barrier. Raising the endogenous
     signal amplifies the local route, not the systemic one.

  ④ THE PHYSIOLOGICAL SIGNAL NEVER PRODUCED THE EFFECT
     Every human being has had normal GLP-1 physiology their entire life.
     It has never produced fifteen percent weight loss in anyone. The drug
     effect exists precisely BECAUSE it is not physiological.

  ─────────────────────────────────────────────────────────────────────
  Point ④ is the decisive one and requires no measurement at all.

📊 Evidence Rating — supplements claimed to boost endogenous GLP-1

Claim: Dietary supplements that raise endogenous GLP-1 produce weight loss comparable to, or meaningfully approaching, GLP-1 receptor agonist therapy.

Rating: ❌ Hype outpaces evidence.

Why: Endogenous GLP-1 has a one-to-two-minute half-life and normal physiology has never produced pharmacological weight loss in anyone. Modest increases in a postprandial peak are not the same intervention as sustained supraphysiological receptor agonism, and the routes may differ.

What would change it: a randomized controlled trial of a specific product with weight as a pre-specified endpoint, showing a clinically meaningful effect. Note that this is a cheap trial to run, and its general absence in a category this large is informative.

What this rating does NOT say: that fiber is useless, that diet does not affect GLP-1, or that these products do nothing at all. Fiber has genuine benefits. The rating attaches to the comparison being marketed, not to the ingredient.

Notice the structure of that last paragraph, because it is the chapter's methodological point. The ❌ is precise: it attaches to a specific comparative claim. A blanket dismissal would be both wrong and easy to rebut, and would hand the argument to whoever is selling.

The general form of the "boost your own" claim

This pattern recurs across the rest of the book with different hormones, so it is worth extracting.

The claim always has the same shape: a drug works by acting on receptor X; this product raises your endogenous ligand for X; therefore this product does what the drug does, naturally.

And it fails at the same three joints every time.

Magnitude. Therapeutic agonism is almost always supraphysiological by design. If physiological levels produced the therapeutic effect, no drug would have been needed. The gap between endogenous and therapeutic concentrations is usually the entire reason the drug exists.

Duration. Endogenous signals are typically pulsatile or meal-triggered and rapidly terminated (Chapter 3 §3.5). Drugs are engineered for persistence — that is what Chapter 4 was about. Raising a transient signal transiently does not reproduce sustained receptor occupancy.

And the existence proof runs against it. Everyone alive has the endogenous system. If enhancing it modestly produced the drug's effect, the effect would be common rather than pharmaceutical.

Apply this in Chapter 15, where the claim is that a compound raises your own growth hormone; in Chapter 21, where it is that a behavior raises your own oxytocin; and anywhere a product offers a natural route to a pharmaceutical outcome. The three joints are the same, and checking them takes under a minute.

13.9 What a 2030 combination might look like

Forward-looking, and explicitly speculative.

If §13.7's argument is right — that redundancy defeats single-target drugs and that multi-node action is what succeeded — then the direction of travel is combination. That is already visible: tirzepatide hits two receptors, retatrutide three, CagriSema pairs two mechanisms.

Plausible additions, all currently 🔬 or earlier: amylin analogs alongside incretins; agents targeting energy expenditure rather than intake alone; approaches that address leptin sensitivity rather than supplying more ligand; and combinations that permit lower doses of each component to reduce gastrointestinal burden.

And the honest caveats, which matter more than the list.

More targets means more off-target effects. Every added receptor is a set of tissues where the drug now acts. Chapter 8's Case Study 2 cataloged what happened to weight-loss drugs acting on broad systems.

Combination trials are harder. Establishing that A+B beats A requires a comparison against A, not against placebo — a larger, longer, more expensive trial that manufacturers have limited incentive to run.

And counter-regulation does not disappear. Hitting more nodes raises the ceiling on how far the system can be displaced. It does not reset the set point, which means discontinuation likely behaves the same way. Nothing in this chapter suggests a combination will produce durable change after stopping, and readers should be suspicious of any claim that one will.

📋 Your Evidence Dossier

This chapter fills Field 8: Claimed use — separating what is marketed from what is approved.

FIELD 8 — CLAIMED USE
  Approved indication(s)   the exact population and purpose on the label, if any
  Commonly claimed uses    what it is actually marketed or used for
  The gap                  which claimed uses are NOT covered by the approval
  Rating per claimed use   each gets its own — they are different claims
  Who makes each claim     manufacturer, prescriber, seller, community

Worked demonstration — two entries, deliberately contrasting

FIELD 8 — SETMELANOTIDE                                [worked demonstration]
  Approved            Chronic weight management in obesity due to specified rare genetic
                      deficiencies in the leptin–melanocortin pathway (including POMC and
                      leptin receptor deficiency, and certain related conditions).
  Commonly claimed    Essentially none in the consumer space — the drug is expensive,
                      prescribed by specialists, and requires a molecular diagnosis.
  The gap             Minimal. This is one of the few compounds in this book where
                      approved use and actual use are nearly identical.
  Rating              ✅ for the approved population. NOT RATED for common obesity —
                      the pathway is intact there and no evidence supports extension.
  Who claims          The manufacturer, narrowly and accurately.

FIELD 8 — "NATURAL GLP-1 BOOSTER" SUPPLEMENTS         [worked demonstration]
  Approved            None. These are not drugs and carry no approved indication.
  Commonly claimed    Weight loss comparable to or approaching prescription GLP-1
                      agonists; appetite suppression; "activating your body's own
                      Ozempic."
  The gap             Total. There is no approval and the comparative claim is the
                      entire marketing proposition.
  Rating              ❌ for the comparative claim. Note precisely: fiber has real
                      benefits and diet genuinely affects GLP-1 secretion. The ❌
                      attaches to the COMPARISON, not to the ingredient.
  Who claims          Sellers and affiliate marketers; rarely the ingredient's own
                      scientific literature, which is usually more modest.

Put the two side by side. One compound's marketing is narrower than its science. The other's marketing is its entire product. Field 8 is where that difference becomes visible, and it is visible before any evidence is consulted.

Your task

Complete Field 8 for every peptide in your dossier.

The "gap" line is the one that does work. For approved drugs it is usually small and specific — an off-label population, a broader claim than the label supports. For unapproved compounds it is frequently the whole entry, and writing that out is more informative than any individual rating.

And record who makes each claim. A claim made by a manufacturer is subject to regulation; the same claim made by a seller, an affiliate, or a community is not. Chapter 6 §6.4 called this epistemic laundering, and Field 8 is where you catch it in your own dossier.

Conclusion

Appetite is regulated by a redundant network defending a set point, with at least a dozen partly overlapping signals converging on hypothalamic circuitry. That architecture is robust against the loss of any single input — excellent for survival, and the reason single-target appetite drugs underperform.

Leptin is the field's most instructive failure. Discovered in 1994, dramatic in the mouse, and useless in common obesity — because people with obesity have high leptin and the problem is resistance rather than deficiency. It works transformatively in congenital leptin deficiency, a condition affecting a few dozen people. Two ratings, one molecule, at opposite ends of the scale.

Amylin is co-secreted with insulin, overlaps GLP-1's actions from a different tissue, and has produced one approved adjunct (pramlintide) and one active development program (cagrilintide, CagriSema). CagriSema is two molecules in one injection, architecturally different from tirzepatide's single molecule hitting two receptors — tunable ratio, two pharmacokinetic profiles, and neither design obviously superior.

The melanocortin pathway is where the monogenic obesities live, and setmelanotide works spectacularly by acting downstream of the broken step. It is the book's clearest demonstration that a proven mechanism still does not license a broad claim: MC4R agonism helps when MC4R signaling is deficient, and there is no evidence it helps when the pathway works.

PYY and ghrelin keep failing for the same structural reason, and "the hunger hormone" is a nickname doing the same damage that "the love hormone" does in Chapter 21.

And "natural GLP-1 boosters" fail on a point that needs no measurement: every human being has had normal GLP-1 physiology their whole life, and it has never produced pharmacological weight loss in anyone. The drug effect exists because it is not physiological.

And one pattern to carry into Part III. Four times now this book has described the same shape: total deficiency, exact replacement, dramatic response. Insulin in type 1 diabetes. Leptin in congenital leptin deficiency. Setmelanotide in POMC deficiency. Mecasermin in severe IGF-1 deficiency, which Chapter 16 covers.

Every one of them is a molecularly defined absence corrected by supplying or bypassing the missing step, and every one produces an effect that looks less like a treatment than like a correction.

Part III is almost entirely the opposite case — compounds given to people with no established deficiency, to improve a system that is working. That is not automatically illegitimate; plenty of useful medicine improves working systems. But it is a different situation with a different burden of proof, and noticing which case you are in is most of the analysis.

Part II ends here. Chapter 14 opens Part III, where the evidence gets much thinner and the marketing gets much louder.

Key Terms

Leptin — a hormone produced by fat tissue in proportion to fat mass, signaling stored energy availability to the hypothalamus.

Leptin resistance — reduced responsiveness to leptin despite elevated levels; the state characterizing common obesity and the reason leptin failed as a general therapy.

ob/ob mouse — the leptin-deficient mouse strain whose study led to leptin's discovery.

Set point — the body weight or energy-store level that homeostatic mechanisms defend.

Amylin — a 37-amino-acid peptide co-secreted with insulin from beta cells; slows gastric emptying, suppresses glucagon, and promotes satiety.

Pramlintide — a synthetic amylin analog approved as an adjunct to mealtime insulin.

Cagrilintide — a long-acting amylin analog in development for weight management.

Melanocortin system — the hypothalamic circuit in which α-MSH activates and AgRP blocks the MC4R receptor, setting appetite.

POMC — proopiomelanocortin, the precursor cleaved to produce α-MSH and other peptides.

α-MSH — alpha-melanocyte-stimulating hormone; the endogenous MC4R agonist that reduces hunger.

AgRP — agouti-related peptide; blocks MC4R and increases hunger.

MC4R — the melanocortin-4 receptor; the convergence point of the appetite circuit and the most common known monogenic contributor to obesity.

Setmelanotide — an 8-amino-acid cyclic MC4R agonist approved for obesity due to specified rare genetic deficiencies.

Monogenic obesity — severe early-onset obesity caused by a single gene defect.

Peptide YY (PYY) — an intestinal peptide released after meals that reduces food intake.

Ghrelin — a stomach-derived peptide that rises before meals and stimulates appetite; the only substantially orexigenic gut hormone known.

Orexigenic / anorexigenic — appetite-stimulating / appetite-suppressing.

Redundancy — the presence of multiple overlapping signals serving a function, such that loss of one is largely compensated.

Spaced Review

1. (Ch 7) Explain why raising endogenous GLP-1 through diet cannot reproduce the effect of a GLP-1 receptor agonist. Give the strongest of the four reasons and say why it requires no measurement.

2. (Ch 9) CagriSema and tirzepatide are both described as combination approaches. State the architectural difference and one advantage of each design.

3. (Ch 5) Leptin receives ✅ for one population and ❌ for another. Explain what a source loses by describing "leptin" as effective or ineffective without naming the population.

4. (Ch 2) Setmelanotide's mechanism is not merely plausible — it is proven. Explain why that still does not license using it in common obesity, and name the general principle.

5. (Ch 3) Explain what "defended set point" means and use it to predict what happens after discontinuation of any successful appetite drug, including combinations that do not yet exist.